Apyx Medical Co. (NASDAQ:APYX) Short Interest Down 14.6% in November

Apyx Medical Co. (NASDAQ:APYX) was the recipient of a large drop in short interest in the month of November. As of November 30th, there was short interest totalling 120,000 shares, a drop of 14.6% from the November 15th total of 140,500 shares. Based on an average trading volume of 51,300 shares, the days-to-cover ratio is presently 2.3 days. Currently, 0.4% of the shares of the stock are sold short.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Private Advisor Group LLC boosted its holdings in Apyx Medical by 3.9% during the third quarter. Private Advisor Group LLC now owns 322,321 shares of the company’s stock worth $400,000 after buying an additional 12,180 shares in the last quarter. Commonwealth Equity Services LLC increased its position in shares of Apyx Medical by 2.9% during the second quarter. Commonwealth Equity Services LLC now owns 511,561 shares of the company’s stock worth $685,000 after acquiring an additional 14,481 shares during the last quarter. RPg Family Wealth Advisory LLC acquired a new stake in Apyx Medical during the 2nd quarter valued at approximately $101,000. Royce & Associates LP increased its stake in shares of Apyx Medical by 3.4% in the third quarter. Royce & Associates LP now owns 2,582,490 shares of the company’s stock worth $3,202,000 after buying an additional 85,267 shares during the last quarter. Finally, Rathbones Group PLC grew its holdings in Apyx Medical by 148.0% during the 2nd quarter. Rathbones Group PLC now owns 251,334 shares of the company’s stock worth $337,000 after acquiring an additional 150,000 shares in the last quarter. 55.33% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently issued reports on APYX shares. BTIG Research began coverage on Apyx Medical in a report on Thursday, October 17th. They issued a “neutral” rating on the stock. JMP Securities reissued a “market perform” rating on shares of Apyx Medical in a research note on Monday, September 16th. Finally, Craig Hallum upgraded Apyx Medical to a “strong-buy” rating in a report on Thursday, October 24th.

Apyx Medical Trading Down 0.6 %

Apyx Medical stock traded down $0.01 during midday trading on Friday, hitting $1.68. 33,846 shares of the stock were exchanged, compared to its average volume of 80,729. The stock’s 50-day simple moving average is $1.37 and its 200 day simple moving average is $1.34. The stock has a market capitalization of $63.24 million, a price-to-earnings ratio of -2.02 and a beta of 1.27. The company has a current ratio of 5.46, a quick ratio of 4.52 and a debt-to-equity ratio of 3.03. Apyx Medical has a fifty-two week low of $0.97 and a fifty-two week high of $2.80.

Apyx Medical (NASDAQ:APYX) last issued its quarterly earnings data on Friday, November 8th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.01. Apyx Medical had a negative return on equity of 137.98% and a negative net margin of 58.59%. The company had revenue of $11.49 million during the quarter, compared to analyst estimates of $11.66 million. During the same period in the prior year, the business posted ($0.13) earnings per share. On average, equities analysts anticipate that Apyx Medical will post -0.68 EPS for the current year.

About Apyx Medical

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.